LAMP1 and neoplasm: Notably, treatment with Nivolumab induced an inflammatory response primarily in the tumor‐border evidenced by IFNγ, IL‐2, and Perforin secretion alongside increased expression of CD107a on CD8+ T cells, in a donor‐dependent manner.